You are currently browsing the archives for 6 January 2018.
Displaying 1 entry.

The ANDA originated and will be produced by Breckenridge&39.

Breckenridge's latest patent challenge regarding cabazitaxel is an ongoing part of its larger strategy to focus on injectable items. Breckenridge's current injectable portfolio consists of oncology and general injectable items in liquid, pre-loaded and lyophilized syringe forms. Cabazitaxel is Breckenridge's second first-to-file Paragraph IV injectable ANDA submission. As part of its overall technique, Breckenridge can be expanding its sales force so it can better promote Breckenridge's growing portfolio of injectable products.